Friday, July 10, 2026

pharma · Advanced Gastric or Gastroesophageal Junction Cancer · Dwarfism

GeneScience Pharmaceuticals Co

Changchun GeneScience Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Gastric or Gastroesophageal Junction Cancer, Dwarfism, Growth Hormone Deficiency. NovaPh

CN HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
30
Programs
3
Drugs
4
Patents
0
Clinical program

PEG-somatropin

Approved · mab · Growth Hormone Deficiency

PEG-somatropin for Growth Hormone Deficiency is a Approved program (mab) at Changchun GeneScience Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Internal code GenSci 004 CT-2

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Changchun GeneScience Pharmaceutical Co.,
Phase
Approved
Modality
mab
Indication
Growth Hormone Deficiency
Status
active
Trials
1